Iovance Biotherapeutics is a biopharmaceutical company that develops cell-based cancer treatments, primarily using patient-derived immune cells to target solid tumors. The company markets Amtagvi, a personalized T cell therapy for advanced melanoma, and Proleukin, an interleukin-2 product for melanoma and renal cell carcinoma, while maintaining a pipeline of investigational therapies aimed at various cancers including lung, cervical, and head and neck malignancies. The company operates through partnerships with research institutions and pharmaceutical manufacturers and maintains headquarters in Philadelphia.

entry readiness 16 · NOT READY · exit proximity 15

Value area 3.28–9.33 · 28% of 120d volume overhead · moderate overhead